Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

BACKGROUND: The efficacy and safety of ixekizumab (IXE) with and without continuous concomitant methotrexate (MTX), for up to 52 weeks of treatment, were evaluated in patients with active psoriatic arthritis (PsA). METHODS: Patients with active PsA who were biologic-naive (SPIRIT-P1) or had prior in...

Descripción completa

Detalles Bibliográficos
Autores principales: Combe, Bernard, Tsai, Tsen-Fang, Huffstutter, J. Eugene, Sprabery, Aubrey Trevelin, Lin, Chen-Yen, Park, So Young, Kronbergs, Andris, Hufford, Matthew M., Nash, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839215/
https://www.ncbi.nlm.nih.gov/pubmed/33499913
http://dx.doi.org/10.1186/s13075-020-02388-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839215/
https://www.ncbi.nlm.nih.gov/pubmed/33499913
http://dx.doi.org/10.1186/s13075-020-02388-5

Ejemplares similares